Opportunity Information: Apply for PA 13 264
Apply for PA 13 264
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Synergizing Omic and Symptom Science (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.361 Nursing Research.
- This funding opportunity was created on Jul 9, 2013 and posted on Jul 9, 2013.
- Applicants must submit their applications by Sep 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: City or township governments Small businesses Private institutions of higher education County governments Special district governments Native American tribal governments (Federally recognized) Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Synergizing Omic and Symptom Science (R01) funding opportunity (PA 13-264) is a National Institutes of Health (NIH) research grant announcement designed to push symptom science forward by connecting two worlds that are often studied separately: the molecular and biological mechanisms inside the body (for example, genomic, proteomic, metabolomic, epigenomic, microbiome, and other "omics" measures) and the outcomes patients report directly about how they feel and function. The central idea is to support projects that deliberately integrate these different layers of information so researchers can better understand why symptoms arise, why they differ from person to person, how they change over time, and how that knowledge can be used to improve symptom assessment, prediction, and ultimately management. The FOA explicitly emphasizes patient-reported outcomes, including symptoms, functional status, and health-related quality of life, and encourages research that links these outcomes to underlying biological processes rather than treating them as separate endpoints.
This opportunity falls under the NIH R01 mechanism, meaning it is intended for full-scale, hypothesis-driven or discovery-oriented research projects that typically require a substantial, multi-year effort. It is categorized as a discretionary grant and is tied to the health and education funding activity areas, with the CFDA listing of 93.361 (Nursing Research), indicating strong alignment with NIH-supported nursing and symptom science priorities. The announcement was posted and created on July 9, 2013, with an original and final closing date of September 7, 2016, and it was archived on October 8, 2016. Cost sharing or matching is not required, which is typical for many NIH research grants and lowers barriers for applicants who may not have access to non-federal matching funds.
A notable feature of this FOA is the broad eligibility landscape. A wide range of U.S. domestic entities can apply, including public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (both those with and without 501(c)(3) status, excluding higher education institutions in that category), for-profit organizations (including small businesses and other for-profit entities), and multiple levels of government (state, county, city or township, special district). It also includes independent school districts and public housing authorities/Indian housing authorities. The eligibility language extends further to include a variety of mission-focused and community-rooted organizations and institutions such as faith-based and community-based organizations, Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). Importantly, the FOA also allows non-U.S. participation: foreign organizations and foreign institutions are eligible to apply, non-domestic components of U.S. organizations are eligible, and foreign components (as NIH defines them) are allowed. This signals NIH interest in high-quality, globally relevant science, especially where international cohorts, specialized omics capabilities, or unique populations may strengthen the research.
In practical terms, the FOA is aimed at research that does more than collect omics data and administer symptom questionnaires in parallel. It is geared toward studies that meaningfully integrate these data types to generate deeper biological insight into patient experiences. That can include identifying biomarkers or molecular signatures associated with specific symptoms or symptom clusters, mapping biological pathways that correlate with symptom severity or persistence, understanding heterogeneity in symptom experiences across individuals, and improving the measurement and interpretability of patient-reported outcomes by anchoring them to biological processes. The integration focus also implies an interest in analytic strategies capable of handling high-dimensional biological data alongside longitudinal symptom trajectories, potentially supporting more personalized or precision approaches to symptom prediction and intervention.
The sponsoring agency is the National Institutes of Health, and the official announcement is hosted through the NIH grants guide. For technical issues accessing the announcement or resolving link problems, the contact provided is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV, reflecting that the primary point of contact in the source excerpt is support for accessing the FOA materials rather than a scientific program contact.
Overall, PA 13-264 can be understood as a targeted NIH effort to accelerate translational symptom science by connecting mechanistic biology with what patients actually report and experience in daily life. It encourages interdisciplinary approaches that bring together omics expertise, clinical and behavioral symptom measurement, and robust data integration, with the longer-term goal of improving how symptoms are explained, anticipated, and addressed in real-world care.
Frequently Asked Questions (FAQs): Synergizing Omic and Symptom Science (R01) - PA 13-264
What is the Synergizing Omic and Symptom Science (R01) opportunity (PA 13-264)?
PA 13-264 is a National Institutes of Health (NIH) research funding opportunity that supports R01 projects aimed at advancing symptom science by deliberately connecting biological "omics" data with patient-reported outcomes (PROs) such as symptoms, functional status, and health-related quality of life.
What is the main goal of this funding opportunity?
The central goal is to push symptom science forward by integrating molecular and biological mechanisms (for example, genomic, proteomic, metabolomic, epigenomic, microbiome, and other omics measures) with what patients report about how they feel and function. The intent is to better understand why symptoms arise, why they vary across people, how they change over time, and how that knowledge can improve symptom assessment, prediction, and management.
What kinds of data does the FOA emphasize?
The FOA emphasizes two data layers that are often studied separately: (1) omics and other biological measures and (2) patient-reported outcomes, including symptoms, functional status, and health-related quality of life. It encourages research that links patient-reported outcomes to underlying biological processes rather than treating them as isolated endpoints.
What does "synergizing omic and symptom science" mean in practice?
It means studies should do more than collect omics data and symptom questionnaires side-by-side. The FOA is geared toward projects that meaningfully integrate these data types to generate biological insight into patient experiences, such as identifying biomarkers or molecular signatures tied to symptoms or symptom clusters and mapping biological pathways associated with symptom severity or persistence.
What types of research questions fit this announcement?
Based on the description, relevant questions include: why certain symptoms occur, why symptom experiences differ from person to person, how symptoms evolve over time, which biological pathways correlate with symptom trajectories, and how integrated biology-plus-PRO models can improve symptom measurement, interpretability, prediction, and management.
Is this a clinical care program or a research grant?
This is a research grant announcement under the NIH R01 mechanism. It is intended to fund full-scale research projects rather than deliver clinical services as a program.
What funding mechanism does PA 13-264 use?
This opportunity uses the NIH R01 mechanism, which is typically used for substantial, multi-year, full-scale research efforts that may be hypothesis-driven or discovery-oriented.
Is this a discretionary grant?
Yes. The opportunity is categorized as a discretionary grant.
What activity areas are associated with this opportunity?
The opportunity is tied to health and education activity areas.
What CFDA program is associated with this FOA?
The CFDA listing is 93.361 (Nursing Research), signaling alignment with NIH-supported nursing research and symptom science priorities.
When was this FOA posted, and what were the closing dates?
The announcement was posted and created on July 9, 2013. The original and final closing date was September 7, 2016. The opportunity was archived on October 8, 2016.
Is this funding opportunity still open?
No. Based on the provided dates, the final closing date was September 7, 2016, and it was archived on October 8, 2016.
Is cost sharing or matching required?
No. Cost sharing or matching is not required for this opportunity.
Who is eligible to apply within the United States?
The FOA describes a broad set of eligible U.S. domestic applicants, including public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (with and without 501(c)(3) status, excluding higher education institutions in that category), for-profit organizations (including small businesses), and multiple levels of government (state, county, city or township, special district). It also includes independent school districts and public housing authorities/Indian housing authorities.
Are community-rooted and mission-focused organizations eligible?
Yes. The eligibility language explicitly includes faith-based and community-based organizations, along with multiple categories of minority-serving and mission-focused institutions.
Which minority-serving institutions are explicitly mentioned as eligible?
The FOA includes Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Can for-profit organizations apply?
Yes. For-profit organizations, including small businesses and other for-profit entities, are listed as eligible applicants.
Can government entities apply?
Yes. Eligibility includes state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.
Are foreign organizations or institutions eligible to apply?
Yes. The FOA states that foreign organizations and foreign institutions are eligible to apply.
Are non-U.S. components of U.S. organizations allowed?
Yes. Non-domestic components of U.S. organizations are eligible.
Are "foreign components" allowed under NIH definitions?
Yes. The FOA indicates that foreign components (as NIH defines them) are allowed.
Why would the FOA allow international participation?
Based on the description, this signals NIH interest in high-quality, globally relevant science, including projects where international cohorts, specialized omics capabilities, or unique populations could strengthen the research.
Does the FOA prioritize patient-reported outcomes (PROs)?
Yes. The FOA explicitly emphasizes patient-reported outcomes, including symptoms, functional status, and health-related quality of life.
Does the FOA require linking PROs to biology?
The FOA encourages research that links patient-reported outcomes to underlying biological processes rather than treating them as separate endpoints.
What omics domains are mentioned?
The FOA description references genomic, proteomic, metabolomic, epigenomic, microbiome, and other omics measures.
What types of outputs or advances does the FOA appear to encourage?
The description highlights goals such as identifying biomarkers or molecular signatures associated with symptoms or symptom clusters, mapping biological pathways correlated with symptom severity or persistence, explaining heterogeneity in symptom experiences, and improving PRO measurement and interpretability by anchoring them to biological processes.
Does the FOA support research on symptom clusters?
Yes. The description specifically mentions biomarkers or molecular signatures associated with specific symptoms or symptom clusters.
Does the FOA encourage longitudinal symptom research?
Yes. The description emphasizes understanding how symptoms change over time and mentions longitudinal symptom trajectories in the context of integrating them with high-dimensional biological data.
What analytic considerations are implied by this FOA?
The FOA implies interest in analytic strategies that can handle high-dimensional omics data alongside symptom outcomes, including longitudinal trajectories, to support more personalized or precision approaches to symptom prediction and intervention.
What is the sponsoring agency?
The sponsoring agency is the National Institutes of Health (NIH).
Where is the official announcement hosted?
The official announcement is hosted through the NIH grants guide.
Who should be contacted for technical issues accessing the announcement?
For technical issues accessing the announcement or resolving link problems, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Is the listed contact a scientific/program contact?
No. The provided contact is described as support for accessing the FOA materials (technical/link issues) rather than a scientific program contact.
Browse more opportunities from the same category: Education Health
Next opportunity: Mid Scale Innovations Program
Previous opportunity: Synergizing Omic and Symptom Science (R15)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 13 264
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 13 264) also looked into and applied for these:
| Funding Opportunity |
|---|
| Grand Opportunity in Medications Development for Substance Use Disorders (U01) Apply for PAR 13 270 Funding Number: PAR 13 270 Agency: National Institutes of Health Category: Education Health Funding Amount: $5,000,000 |
| Revision Applications to Promote Collaborative Research on Addiction at NIH (CRAN) Comorbidity Related Research (R01) Apply for RFA DA 14 014 Funding Number: RFA DA 14 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Administrative Supplements to Promote Collaborative Research on Addiction at NIH (CRAN) Comorbidity Related Research (Admin Supp) Apply for PA 13 275 Funding Number: PA 13 275 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Abuse Resistant and Abuse Deterrent Formulations and Devices to Avoid the Abuse, Misuse and Diversion of Prescription Opioids by Patients (SBIR)(R43/R44) Apply for RFA DA 14 013 Funding Number: RFA DA 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PAR 13 282 Funding Number: PAR 13 282 Agency: National Institutes of Health Category: Education Health Funding Amount: $175,000 |
| NLM Career Development Award in Biomedical Informatics (K01) Apply for PAR 13 284 Funding Number: PAR 13 284 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Building Evidence Effective Palliative/End of Life Care Interventions (R01) Apply for PAR 13 289 Funding Number: PAR 13 289 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NLM Express Research Grants in Biomedical Informatics (R01) Apply for PAR 13 300 Funding Number: PAR 13 300 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Advanced Development of Informatics Technology (U24) Apply for PAR 13 294 Funding Number: PAR 13 294 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Revisions to P01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P01) Apply for PAR 13 297 Funding Number: PAR 13 297 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions to P50 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P50) Apply for PAR 13 298 Funding Number: PAR 13 298 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P01) Apply for PAR 13 317 Funding Number: PAR 13 317 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P50) Apply for PAR 13 318 Funding Number: PAR 13 318 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| National Cancer Institute Program Project Applications (P01) Apply for PAR 13 321 Funding Number: PAR 13 321 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Increased Knowledge and Innovative Strategies to Reduce HIV IncidenceiKnow Projects (R01) Apply for PAR 13 323 Funding Number: PAR 13 323 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (SBIR R43/44) Apply for PAR 13 327 Funding Number: PAR 13 327 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revisions for Early Stage Development of Informatics Technology (P01) Apply for PAR 13 330 Funding Number: PAR 13 330 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Health Promotion Among Racial and Ethnic Minority Males (R21) Apply for PA 13 331 Funding Number: PA 13 331 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) Apply for PAR 13 334 Funding Number: PAR 13 334 Agency: National Institutes of Health Category: Education Health Funding Amount: $3,000,000 |
| Neuroscience Research on Drug Abuse (R21) Apply for PA 13 337 Funding Number: PA 13 337 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 13 264", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.